On September 16, 2021 CureLab Oncology’s a clinical-stage biotech company, reported that is featured at this year’s European Society for Medical Oncology (Press release, CureLab Oncology, SEP 16, 2021, View Source [SID1234587815]). Two reports were accepted and are featured as e-posters in the oncology/PRO educational portal for oncologists.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The reports describe findings resulting from CureLab’s clinical trials of Elenagen, an experimental DNA therapy, that are currently underway at N.N. Alexandrov National Cancer Centre of Belarus under the direction of a team led by Deputy Director Professor Sergei Krasny, MD, DSc.

The reports are available online:

Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients
Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer
About Elenagen
CureLab’s lead investigational compound is code-named Elenagen, an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In animal studies and Phase I/II human trials conducted ex-US, Elenagen has shown promise in reversing tumor grade, changing the tumor microenvironment, and enhancing the anti-cancer effects of chemotherapy. Experimental results indicate a mitigation of chronic inflammation and stimulation of an immune response to the tumor.